Agile Drug Development Required in a New Age of Urgency
Srinivas (Srini) Shankar, Senior VP, Global Head – Life Sciences, Cognizant
Ulo Palm, M.D., Ph.D., Senior VP – Digital Sciences, Allergan; Corporate Secretary, TransCelerate BioPharma Inc.
Thomas A. Bock, M.D., MBA, Founder, HeritX; Chairman, Healthcare Advisory Board, Columbia Business School; former Senior VP, Global Head – Medical Affairs, Alexion Pharmaceuticals
Taren Grom, Editor, PharmaVOICE
Viruses now travel at the speed of sound across the world. Viruses don’t recognize borders. Viruses with no approved treatments will continue to impact thousands of people globally. To protect humanity from the next pandemic, the current paradigm of drug development, clinical trials, and regulatory approvals requires the medical community, life-sciences industry, health institutions, government and regulatory bodies to act with a sense of urgency. All stakeholders need to examine any and all recommendations that bear a promise to delay or stop the spread of global pandemics in a matter of weeks and not in a matter of months or years.
An expert panel will discuss how out-of-the-box thinking and technology can be applied to counter future global health emergencies.
About the Sponsors
Cognizant (Nasdaq-100: CTSH) is one of the world's leading professional services companies, transforming clients' business, operating and technology models for the digital era. Our unique industry-based, consultative approach helps clients envision, build and run more innovative and efficient businesses.For more information please visit www.cognizant.com/lifesciences.